Moderna's growth story is just beginning.

Moderna's flu vaccine may not fuel a further recovery for the hard-hit COVID-19-affected stock.

When a stock and the analysts covering it disagree this sharply, one of them is about to be wrong.

Moderna (MRNA) climbed to $81.42, up 169% annually. Analysts set average target at $37 while insiders sold $6.1M worth of ...

Moderna shares rose nearly 20% after Science Day, driven partly by a short squeeze, while its mRNA pipeline beyond vaccines ...

Shares of Moderna (NASDAQ:MRNA | MRNA Price Prediction) are up 14% to $68 and change in afternoon trading Friday, extending a ...

Moderna just received fantastic news.

The stock is rerating because it’s moving from “COVID vaccine story” to a real platform: first-in-vivo CAR-T (mRNA-6007) plus ...

Moderna (NASDAQ:MRNA) stock is jumping again. Shares are up 9% today, trading near $57 in the Tuesday afternoon session. That extends a remarkable 2026 run for the mRNA pioneer. The move pushes ...

Moderna, Inc. (NASDAQ:MRNA) was among the stocks Jim Cramer commented on as he advised investors on how to take advantage of ...

The "Mad Money" host revisits a stock he spent years dismissing.